Cafcit 5 mg Solution
PDF Leaflet Revision Date: 31 October 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of primary apnoea of premature newborns.
Dosage (summary)
Loading dose: 20 mg/kg IV over 30 mins; Maintenance: 5 mg/kg IV or orally every 24 hours.
Onset of Action / Duration
Onset: minutes, Duration: prolonged half-life in neonates.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Caffeine crosses placenta and is excreted in breast milk; breastfeeding mothers should avoid caffeine.
Key Drug Interactions
- Theophylline
- Cimetidine
- Ketoconazole
- Phenobarbital
- Phenytoin
Contraindications
- Hypersensitivity to caffeine citrate
Common side effects
- Irritability
- Jitteriness
- Tachycardia
- Hypoglycaemia
- Necrotising enterocolitis
Counselling Points
- Monitor for apnoea recurrence
- Avoid caffeine in breastfeeding
- Report any unusual symptoms
Serious warnings
- Monitor plasma caffeine levels
- Risk of seizures
- Caution in cardiac disease
Important Disclaimer
The Cafcit 5 mg Solution professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
